New Report Reveals Alarming Decline in Women’s Cancer Testing Worldwide
21.1.2025 14:00:00 CET | Business Wire | Press release
Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index, one of the largest collections of data on women’s health and well-being.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121461870/en/
Hologic, Inc. (Nasdaq: HOLX), a leading women’s health innovator, partners with Gallup to create the Index. Now in its fourth year, the Index raises new concerns about declining trends in women’s health. For the first time in the history of the Index, women’s cancer testing declined: Only 10% of women surveyed worldwide said they were tested for any type of cancer in the past year, down two percentage points from the first two years of the Index.
This year’s Index will be released today during an event convened by Goals House, a community focused on driving progress toward the United Nations (UN) Sustainable Development Goals (SDGs) alongside the World Economic Forum in Davos, Switzerland. The event will feature a panel including Dr. Natalia Kanem, Executive Director of the United Nations Population Fund (UNFPA), Dr. Sania Nishtar, CEO, Gavi, The Vaccine Alliance and Elissa Miolene, Global Development Reporter, Devex.
“Today’s data reveal a worsening trend in women’s health,” said Stephen P. MacMillan, Chairman, President and CEO of Hologic. “The shocking decline in cancer testing is a wake-up call. Business as usual is not working. Innovative strategies and collaborative efforts are needed to make sustained improvements in women’s health and well-being around the world.”
Key findings from this year’s Index:
- Cancer Screening Among Women Declined: Only 10% of women said they underwent any type of cancer testing in the past year, reflecting a decrease of two percentage points from the first two years of the survey.
- Women Are Struggling More to Meet Basic Needs: A staggering 38% of women reported being unable to afford food at some point in the past year, marking the highest level of food insecurity in nearly two decades. And 32% of women said they could not afford adequate shelter.
- More Women Are Worried and Sad: More women reported feeling worried (42%) and sad (30%) compared to Year 1 of the Index. And over one third (35%) said they felt unsafe in their communities.
- Ongoing Physical Pain and Health Issues:34% of women reported experiencing significant pain the previous day, while 26% indicated that health problems impacted their ability to engage in everyday activities.
- HIV Testing Rates for Women Are Alarmingly Low: The Index assessed women’s HIV testing for the first time and found concerning disparities: Less than0.5% of women were tested in certain countries, primarily those in the Middle East and North Africa, and no country scored above 41%. Globally, the percentage is much lower. Just 6% of women — regardless of whether they visited a healthcare professional or were tested for STIs — said they were tested for HIV in the past year.
- Signs of Hope — Some Countries Are Making Progress:28 countries saw meaningful increases in their Index scores since the first year of the Index, including Kazakhstan, Kenya, Poland and Venezuela.
The Index assigns a women’s health score to each country or territory based on survey responses on five dimensions of health. Overall, the world scored 53 out of 100 on the Index in Year 4, reflecting no significant change since the Index started.
Taiwan led the world for the fourth consecutive year, scoring 68 out of a possible 100. Other top scores went to Kuwait (67), Austria (66) and Switzerland (65). The lowest scores went to Afghanistan (30), the Democratic Republic of Congo (34) and Chad (35). The United States scored 60 – on par with New Zealand (60) and Lithuania (60) – and fell seven places from its ranking in the third year of the Index to 37 out of 142 countries and territories.
The Index fills a critical gap in knowledge about the health, safety and well-being of women worldwide. Based on interviews with more than 146,000 women and men in 142 countries and territories, it represents the voices of 97% of the world’s women and girls aged 15 and older.
To see the full Index and related resources, visit WomensHealthIndex.com.
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health, dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.
Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
About Gallup
Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121461870/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom